dasatinib (sprycel) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Dasatinib [BMS 354825] is an orally active, small molecule, dual inhibitor of both SRC and ABL kinases that is under development with Bristol-Myers Squibb for the treatment of patients with chronic myelogenous leukaemia (CML) and imatinib-acquired resistance/intolerance. It’s used for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. While imatinib remains a frontline therapy for CML, patients with advanced disease frequently develop resistance to imatinib therapy through multiple mechanisms. Dasatinib is also undergoing preclinical evaluation for its potential as a therapy against multiple myeloma. Bristol-Myers Squibb has a composition-of-matter patent covering this research approach that will expire in 2020. Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase.   NCATS

  • Mol. Mass: 488.006
  • ALogP: 3.31
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)


$32.9785 - $107.7321

United States

$91.7648 - $487.0428
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

anh. dasatinib | anhydrous dasatinib | bms-354825 | bms-354825-03 | bms dasatinib | dasatinib | dasatinib (anh.) | dasatinib (anhydrous) | dasatinib hydrate | dasatinibum | n-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide | sprycel | spyrcel


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue